RANI (Rani Therapeutics Holdings) Total Operating Expense: $37.81 Mil (TTM As of Mar. 2026)


RANI Rani Therapeutics Holdings Inc RANI
32 GF Score
Price $0.76
! 3 Warning Signs
View Full Analysis

What is Rani Therapeutics Holdings Total Operating Expense?

Rani Therapeutics Holdings RANI +3.91% 32 Total Operating Expense is $37.81 Mil as of Mar. 2026. GuruFocus rates RANI with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

Rani Therapeutics Holdings's Total Operating Expense for the three months ended in Mar. 2026 was $10.05 Mil. Rani Therapeutics Holdings's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $37.81 Mil.

Rani Therapeutics Holdings Total Operating Expense Related Terms

Rani Therapeutics Holdings Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Rani Therapeutics Holdings's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rani Therapeutics Holdings Total Operating Expense Chart

Rani Therapeutics Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial 54.32 63.45 66.10 50.63 39.94

Rani Therapeutics Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.19 10.51 7.26 10.00 10.05
RANI
32GF Score
Rani Therapeutics Holdings Inc RANI
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rani Therapeutics Holdings Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $37.81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $37.81 Mil mean?
Rani Therapeutics Holdings (RANI) has a Total Operating Expense of $37.81 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Rani Therapeutics Holdings and its competitors.
Is Rani Therapeutics Holdings' Total Operating Expense too high?
Rani Therapeutics Holdings' current Total Operating Expense is $37.81 Mil. Overall, Rani Therapeutics Holdings has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Rani Therapeutics Holdings' Total Operating Expense compare to IBIO and RNTX?
Rani Therapeutics Holdings' Total Operating Expense of $37.81 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Rani Therapeutics Holdings and its competitors. Rani Therapeutics Holdings's current Total Operating Expense is $37.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rani Therapeutics Holdings stock overvalued right now?
Rani Therapeutics Holdings (RANI) has a current Total Operating Expense of $37.81 Mil. The current Total Operating Expense is $37.81 Mil. Rani Therapeutics Holdings' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Rani Therapeutics Holdings (RANI), the current Total Operating Expense is $37.81 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rani Therapeutics Holdings Business Description

Address 2051 Ringwood Avenue, San Jose, CA, USA, 95131
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
32GF Score

Get the complete analysis for RANI

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.76
Price